Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Waikato Hospital Waikato Hospital Research Fund |
---|---|
Information provided by: | Waikato Hospital |
ClinicalTrials.gov Identifier: | NCT00745043 |
Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These are very common conditions and many patients have both diseases. Beta-blocker drugs are extensively used in the treatment of angina, high blood pressure and after heart attacks to decrease symptoms and prolong life. Beta-agonists are used in COPD to decrease breathlessness and improve exercise tolerance. It used to be thought that beta-blockers cannot be used in COPD patients as they may make the breathlessness worse, but it has now been established that they can be used safely. Beta-blocker drugs and beta-agonists have 'opposite' effects on the body and the investigators do not know if they can work together or if they would cancel each other out. The investigators also do not know which of the different types of beta-blockers now available are better for COPD patients. This study will investigate what happens to the airways of people taking both of these drugs.
Condition | Intervention |
---|---|
Chronic Obstructive Pulmonary Disease |
Drug: bronchodilator response |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | Do Beta-Blockers Affect the Use of Beta-Agonist Inhalers in COPD? |
Enrollment: | 11 |
Study Start Date: | May 2005 |
Study Completion Date: | August 2007 |
Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
R302: Placebo Comparator
Daily placebo capsules
|
Drug: bronchodilator response |
R303: Active Comparator
Daily metoprolol 95mg capsules
|
Drug: bronchodilator response |
R304: Active Comparator
Daily propranolol 80mg capsules
|
Drug: bronchodilator response |
Open Label: Active Comparator
Daily Metoprolol 190mg capsules
|
Drug: bronchodilator response |
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
New Zealand, Waikato | |
Department of Respiratory Medicine | |
Hamilton, Waikato, New Zealand, 3204 |
Study Director: | Bob Hancox, MD FRACP | Waikato Hospital Research Unit |
Responsible Party: | Respiratory Research Waikato Hospital ( Dr Catherina Chang Research Fellow ) |
Study ID Numbers: | NTX/05/04/035 |
Study First Received: | August 29, 2008 |
Last Updated: | August 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00745043 |
Health Authority: | New Zealand: Health and Disability Ethics Committees |
COPD Betablockers bronchodilator exercise capacity methacholine challenge |
Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Methacholine Chloride Respiration Disorders Pulmonary Disease, Chronic Obstructive |